Trial Profile
A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Sapacitabine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Cyclacel Pharmaceuticals
- 23 Jan 2019 Status changed from active, no longer recruiting to completed.
- 28 Oct 2018 Planned primary completion date changed from 1 Nov 2011 to 1 Dec 2018.
- 21 Apr 2015 Status changed from recruiting to active, no longer recruiting as per M.D. Anderson Cancer Center.